EU/3/05/310

Table of contents

About

On 26 August 2005, orphan designation (EU/3/05/310) was granted by the European Commission to United Therapeutics Europe Ltd., United Kingdom, for treprostinil diethanolamine (oral use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.

Key facts

Active substance
Treprostinil diethanolamine (oral use)
Disease / condition
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Date of decision
26/08/2005
Outcome
Positive
Orphan decision number
EU/3/05/310

Sponsor's contact details

Unither Therapeutik GmbH
Dreieichstrasse 11
64546 Moerfelden-Walldorf
Germany
Tel. +49 6105 27137

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • HTAP France : Association Française d'aide aux patients souffrant d'Hypertension Artérielle Pulmonaire
    31 Rue Jacques Cellier
    51100 Reims
    France
    Telephone: +33 3 26 36 93 32
    E-mail : secretariat@htapfrance.com
  • PH : Pulmonale Hypertonie e.V.
    Wormser Str. 20
    76287 Rheinstetten
    Germany
    Telephone: +49 49 72 42 72 94
    Telefax: +49 72 42 95 26 67
    E-mail : pphev@aol.com
  • Pulmonary Hypertension Association
    PO Box 2760
    Lewes
    Sussex
    BN8 4WA
    United Kingdom
    Telephone: +44 800 389 81 56
    Telefax: +44 70 10 71 57 23
    E-mail: pha_uk@hotmail.com

How useful was this page?

Add your rating